Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Turner syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Turner syndrome. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-001881-14 Sponsor Protocol Number: 20072650 Start Date*: 2021-03-19
    Sponsor Name:Department of Endocrinology and Internal Medicine, Aarhus University Hospital
    Full Title: Endocrine, cardiovascular, pharmacologic and physiologic aspects of sex hormone treatment in Turner syndrome - project part 1
    Medical condition: Ovarian dysgenesis and related hypogonadism caused by Turner syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10045181 Turner's syndrome PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004934-40 Sponsor Protocol Number: 20072651 Start Date*: 2021-03-19
    Sponsor Name:Department of Endocrinology and Internal Medicine, Aarhus University Hospital
    Full Title: Endocrine, cardiovascular, pharmacologic and physiologic aspects of sex hormone treatment in Turner syndrome - project part B
    Medical condition: Ovarian dysgenesis and related hypogonadism causes by Turner syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10045181 Turner's syndrome PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000460-10 Sponsor Protocol Number: EMR200104_10 Start Date*: 2011-08-03
    Sponsor Name:Merck Serono SA
    Full Title: First year growth response associated genetic markers validation Phase IV open-label study in Growth Hormone Deficient and Turner Syndrome pre-pubertal children : the PREDICT Pharmacogenetics V...
    Medical condition: idiopathic growth hormone deficienty Turner Syndrome
    Disease: Version SOC Term Classification Code Term Level
    13.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    13.1 10010331 - Congenital, familial and genetic disorders 10045181 Turner's syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010280-17 Sponsor Protocol Number: TSHYPE-2601-2009 Start Date*: 2009-04-17
    Sponsor Name:Organisation name was not entered
    Full Title: TS HYPE - Turner syndrome and Hypertension; a double-blinded randomised interventional trial.
    Medical condition: Turner syndrome, hypertension and aortopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045181 Turner's syndrome LLT
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001502-42 Sponsor Protocol Number: B9R-US-GDGH Start Date*: 2016-06-23
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Effect of Early Growth Hormone Treatment on Long-term Growth and Skeletal Maturation in Girls With Turner Syndrome
    Medical condition: Turner Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10063020 Parsonage-Turner syndrome LLT
    Population Age: Children, Under 18 Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005510-21 Sponsor Protocol Number: 2005-BH-GH Start Date*: 2006-06-08
    Sponsor Name:Medical Department M, Aarhus Sygehus
    Full Title: GH treatment of women with Turner syndrome. Body composition and heart function.
    Medical condition: Kvinder med Turner syndrom er især karakteriserede ved vækstretardering med reduceret sluthøjde samt ved at være hypogonade og infertile. Der udover ses en øget comorbiditet for en række andre sygd...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004778-99 Sponsor Protocol Number: 120895 Start Date*: 2005-06-14
    Sponsor Name:Pediatric Unit, Hillerød Hospital
    Full Title: The growth of the internal genitalia and the bone mineralization during hormonal replacement therapy and the presence of aortic root dilatation in girls with Turner Syndrome
    Medical condition: Turner Syndrome is a common chromosomal abnormalities, characterized by one X-chromosome or a partial deletion in all or some cell-lines. The syndrome is known for features as short stature and abs...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003392-10 Sponsor Protocol Number: CMEK162Y2201 Start Date*: 2012-01-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy.
    Medical condition: Noonan syndrome hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    14.1 10007541 - Cardiac disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-000750-22 Sponsor Protocol Number: GHLIQUID-4020 Start Date*: 2018-04-12
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial investigating the long-term efficacy and safety of two doses of NN-220 (somatropin [genetical recombination]) in short stature due to Noonan syndrome
    Medical condition: Noonan Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-000042-37 Sponsor Protocol Number: GHNOO-1658 Start Date*: 2005-07-11
    Sponsor Name:Novo Nordisk A/S
    Full Title: Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit
    Medical condition: Noonan syndrome associated short stature
    Disease: Version SOC Term Classification Code Term Level
    7.1 10029748 PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005022-10 Sponsor Protocol Number: SYN-1748-MAL-0030-I Start Date*: 2018-02-13
    Sponsor Name:Technische Universität München, Fakultät für Medizin
    Full Title: Improvement of synaptic plasticity and cognitive function in RAS pathway disorders
    Medical condition: Noonan Syndrom and Neurofibromatosis Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10029268 Neurofibromatosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005054-31 Sponsor Protocol Number: 24531 Start Date*: 2005-07-15
    Sponsor Name:Serono International S.A.
    Full Title: A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with Saizen
    Medical condition: - growth failure in children caused by decreased or absent secretion of endogenous growth hormone. - growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal anal...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10056438 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) ES (Completed) DE (Completed) AT (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005607-13 Sponsor Protocol Number: NN8640-4467 Start Date*: 2022-07-15
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with ...
    Medical condition: Short stature born small for gestational age Turner syndrome Noonan syndrome Idiopathic short stature
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10045181 Turner's syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    23.0 100000004859 10066333 Idiopathic short stature LLT
    21.1 100000004868 10041093 Small for gestational age LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) SI (Trial now transitioned) IE (Completed) DE (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001539-31 Sponsor Protocol Number: FE999905 CS002 Start Date*: 2005-09-16
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-label, Multi-centre, Phase III Study of Local Tolerability of Zomacton 10 mg (Recombinant Somatropin) administered by ZomaJet Vision X
    Medical condition: Zomacton is indicated for the long term treatment of children who have growth failure due to inadequate secretion of growth hormone and for the long-term treatment of growth retardation due to Turn...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-001721-26 Sponsor Protocol Number: B9R-EW-GDFC(a) Start Date*: 2006-09-25
    Sponsor Name:UAB “Eli Lilly Lietuva”
    Full Title: The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)
    Medical condition: Short Stature
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000356-17 Sponsor Protocol Number: 2 79 58035 700 Start Date*: Information not available in EudraCT
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ USING A NOVEL CAPILLARY BLOOD COLLECTION METHOD
    Medical condition: growth failure associated with: - inadequate growth hormone secretion - Turner syndrome, confirmed by karyotype - chronic renal insufficiency up to renal transplantation
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed) DK (Completed) AT (Completed) SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-001674-32 Sponsor Protocol Number: NordiNet-IOS Start Date*: 2009-04-29
    Sponsor Name:Novo Nordisk Farma Oy
    Full Title: NordiNet International Outcome Study (NordiNet IOS)
    Medical condition: Small Gestation Age, Turner Syndrome, Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-017387-16 Sponsor Protocol Number: GH-3826 Start Date*: 2010-08-31
    Sponsor Name:Novo Nordisk Pharmaceutique S.A.S
    Full Title: To assess ease of use, acceptability and preference of Norditropin NordiFlex® in subjects on prescribed growth hormone therapy
    Medical condition: children aged 6 years or more receiving growth hormone therapy for the following approved indications (according to Norditropine SPC) -GHD -Turner Syndrome -small for gestational age -chronic rena...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005166-12 Sponsor Protocol Number: HMPL-004-US-02 Start Date*: 2008-07-29
    Sponsor Name:Hutchison MediPharma Enterprises Limited
    Full Title: A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine
    Medical condition: active mild to moderate ulcerative colitis defined as a Mayo clinical score of 4-10 points
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000362-53 Sponsor Protocol Number: QOLONERev2MDS Start Date*: 2016-11-23
    Sponsor Name:ASSOCIAZIONE QOL-ONE
    Full Title: Efficacy of eltrombopag plus lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, ...
    Medical condition: Adult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with isolated del(5q)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10028536 Myelodysplastic syndromes HLT
    19.0 100000004864 10067096 5q minus myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 04:13:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA